AZN earnings

Strong revenue growth and positive readouts from high-value NMEs reinforce confidence in 2030 ambition AstraZeneca: Revenue and EPS summary   Q1 2026 % Change   $m Actual CER1 - Product Sales 14,386 12 7 - Alliance Revenue 825 29 26 Product Revenue 15,211 13 8 Collaboration Revenue 77 4 - Total Revenue 15,288 13 8 Reported EPS ($) 1.99 6 8 Core2 EPS ($) 2.58 4 5 Key performance elements for Q1 2026 (Growth numbers at constant exchange rates) Total Revenue

Strong commercial performance and excellent pipeline delivery in a continuing catalyst-rich period AstraZeneca: Revenue and EPS summary   FY 2025 % Change Q4 2025 % Change   $m Actual CER1 $m Actual CER - Product Sales 55,573 9 9 14,538 9 7 - Alliance Revenue 3,067 39 38 959 34 33 Product Revenue2 58,640 10 10 15,497 10 8 Collaboration Revenue 99 (89) (89) 6 (99) (99) Total Revenue 58,739 9 8 15,503 4

Strong growth momentum continues with excellent R&D pipeline delivery in the year-to-date AstraZeneca: Revenue and EPS summary   H1 2025 % Change Q2 2025 % Change   $m Actual CER1 $m Actual CER - Product Sales 26,670 8 10 13,795 11 10 - Alliance Revenue 1,293 38 38 654 36 35 Product Revenue2 27,963 9 11 14,449 12 11 Collaboration Revenue 82 68 66 8 >2x >2x Total Revenue 28,045 9 11 14,457 12 11

Growth momentum and pipeline delivery set AstraZeneca on a strong trajectory towards 2030 ambition AstraZeneca: Revenue and EPS summary   Q1 2025 % Change       $m Actual CER1       - Product Sales 12,875 6 9       - Alliance Revenue 639 40 42       Product Revenue2 13,514 7 10       Collaboration Revenue 74 64 64       Total Revenue 13,588 7 10       Reported EPS ($) 1.88 34 32       Core3 EPS ($) 2.49 21 21       Key performance elements for Q1 2025 (Growth numbers at constant exchange

STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced changes to its Board of Directors. The Company announced that the Board appointed Louis E. Silverman, who served on the Company's Board from 2014-2022, as a director, effective April 24, 2025. The Company also announced that Aimee S. Weisner, who has served as a director since 2022, has chosen not to stand for re-election to the Board when her term expires at the Company's 2025 annual meeting of shareholders in June. In addition, the Company announced that Wei Jiang, who has served as a director since 2024, has agreed to

Strong momentum in FY 2024 with Total Revenue and Core EPS up 21% and 19% respectively AstraZeneca: Revenue and EPS summary     FY 2024 % Change Q4 2024 % Change $m Actual CERi $m Actual CER - Product Sales 50,938 16 19 13,362 18 19 - Alliance Revenue   2,212 55 55 714 68 69 - Collaboration Revenue 923 56 54 815 >2x >2x Total Revenue   54,073 18 21 14,891 24 25 Reported EPS $4.54 18 29

Upgrade to full year 2024 guidance underpinned by strong underlying growth momentum AstraZeneca: Revenue and EPS summary     9M 2024 % Change Q3 2024 % Change $m Actual CER1 $m Actual CER - Product Sales 37,576 16 19 12,947 18 20 - Alliance Revenue   1,498 49 50 559 48 50 - Collaboration Revenue 108 (66) (66) 59 (39) (40) Total Revenue   39,182 16 19 13,565 18 21 Reported EPS $3.57 11 21

ODD and RPDD granted by the FDA and ODD granted by the European Commission to UCART22 for the treatment of ALLODD granted by the FDA to CLLS52 (alemtuzumab) for ALL treatmentCash position of $273 million as of June 30, 20241; cash runway projection into 2026 NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today provided business updates and reported financial results for the six-month period ending June 30, 2024. "Over the past months, we have achieved a significant milestone with the granting of ODD designations by

Strong underlying growth supports FY 2024 guidance upgrade, with both Total Revenue and Core EPS now expected to increase by a mid teens percentage at CER1 AstraZeneca: Revenue and EPS summary H1 2024 % Change   Q2 2024 % Change $m Actual CER   $m Actual CER - Product Sales 24,629 15 18   12,452 14 18 - Alliance Revenue   939 50 50   482 42 42 - Collaboration Revenue 49 (78) (78)   4 (98) (98) Total Revenue   25,617 15 18   12,938 13 17

•  Cellectis announced completion of the additional equity investment of $140M by AstraZeneca •  Cash position of $143 million as of March 31, 20241; cash runway projection into 20262 •  Conference call and webcast scheduled for tomorrow, May 29, 2024 at 8:00AM ET / 2:00PM CET NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today provided business updates and reported financial results for the three-month period ending March 31, 2024. "We are thrilled to have announced the closing of the additional equity investment of $14

New data for TEZSPIRE and BREZTRI demonstrate AstraZeneca's innovation and commitment to transform care in COPD AstraZeneca will showcase new clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at the American Thoracic Society (ATS) International Conference, in San Diego, CA from May 17 - 22, 2024. The company will present 59 abstracts, including 12 late-breaking posters, with a focus on unmet needs in chronic obstructive pulmonary disease (COPD), severe asthma and eosinophilic granulomatosis with polyangiitis (EGPA), as well as other chronic respiratory diseases. Sharon Barr, Ph.D., Executive Vice President, BioPharmaceuticals R&D,

Very strong revenue and EPS growth in the first quarter coupled with exciting pipeline delivery AstraZeneca: Revenue and EPS summary     Q1 2024 % Change $m Actual CER1 - Product Sales 12,177 15 18 - Alliance Revenue   457 59 59 - Collaboration Revenue 45 66 66 Total Revenue   12,679 17 19 Reported EPS $1.41 21 30 Core2 EPS $2.06 7 13 Financial performance for Q1 2024 (Growth numbers at CER) Total Revenue up 19% to $12,679m, driven by an 18% increase

Additional indication for pediatric patients with severe eosinophilic asthma AstraZeneca's FASENRA® (benralizumab) is now approved by the US Food and Drug Administration (FDA) for add-on maintenance treatment for patients with severe asthma aged 6 to 11 with an eosinophilic phenotype.1 FASENRA was first approved in 2017 as an add-on maintenance for the treatment of severe eosinophilic asthma (SEA) in patients aged 12 and older.1 This additional indication for FASENRA was supported by evidence from TATE, an open-label, multinational, non-randomized, parallel assignment Phase III trial, as well as adequate and well-controlled trials in adult and adolescent populations.2 In the TATE study,

Strong growth and pipeline momentum with three new medicines approved since the third quarter AstraZeneca: Revenue and EPS summary     FY 2023 Q4 2023       % Change   % Change $m Actual   CER1   $m Actual CER - Product Sales 43,789 2   4   11,323 5 5 - Alliance Revenue2   1,428 89   89   424 69 67 - Collaboration Revenue2 594 (1 ) (1 ) 277 75 74 Total Revenue  

-- Achieved $23.8 million in AYVAKIT® (avapritinib) net product revenues, and $62.7 million in total revenues -- -- AYVAKYT® (avapritinib) launch in Germany underway following European Commission approval for advanced SM on March 25 -- -- First patients dosed in BLU-701, BLU-451, and BLU-222 clinical trials; trial cohort initiated for BLU-945 in combination with osimertinib -- -- On track to report topline data for registration-enabling PIONEER trial of AYVAKIT in non-advanced SM in late summer 2022 -- CAMBRIDGE, Mass., May 3, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC) today reported financial results and provided a business update for the first quarter ended March

-- Early dose escalation data show dose-dependent reductions in ctDNA and tumor burden -- -- Generally well-tolerated with most AEs Grade 1 or 2, supporting continued dose escalation -- -- Initiating SYMPHONY trial cohort to evaluate BLU-945 in combination with osimertinib -- -- Clinical trial supply agreement signed with AstraZeneca to provide osimertinib for combination development in ongoing BLU-945 and BLU-701 trials -- -- Blueprint Medicines to host investor conference call and webcast on Friday, April 8 at 2:00 pm ET -- CAMBRIDGE, Mass., April 8, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC) today announced proof-of-concept data from the Phase 1/2 SYMPHONY clinical

Transgene to receive $8 million upfront option exercise payment Conference call today on December 15, 2021, at 6:00 p.m. CET (12:00 p.m. ET) in English (details at the end of the release) Regulatory News: Transgene (PARIS:TNG) (PARIS:TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, announces that AstraZeneca (NASDAQ:AZN) has exercised its first license option for an Invir.IO™ oncolytic virus (OV) developed from their on-going OV collaboration. The exercise of this option for an OV, integrating an undisclosed transgene, will result in Transgene receiving an $8 million payment from AstraZeneca. Transgene is also eligible to receive developme

LONDON and SALT LAKE CITY, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ:RNLX), (LSE: RENX) an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces its results for the twelve months ended 30 June 2021. Highlights: Regulatory & Reimbursement Government-wide contract granted by the U.S. General Services Administration for KidneyIntelX™ testing services at $950 per reportable result; applies to more than 140 U.S. government departments, agencies, and affiliates including U.S. Veterans Administration (VA), Department of Defense military b

 —Combination study to build upon momelotinib's differentiated potential as a cornerstone myelofibrosis therapy-— Sierra Oncology, Inc. (NASDAQ:SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, today announced it has acquired an exclusive global license from AstraZeneca (NASDAQ:AZN) for AZD5153, a potent and selective BRD4 BET inhibitor with a novel bivalent binding mode. Sierra plans to initiate a Phase 2 study examining momelotinib in combination with AZD5153 in myelofibrosis patients in the first half of 2022. "This global in-licensing deal is of two-fold importance to Sierra's long-term strategy. First, it brings